SCHEMBL4496300

SCHEMBL4496300

CCn1c(=O)c(Br)cc2c(C)nc(Nc3ccc(N4CCN(C(=O)OCC(C)C)CC4)cc3)nc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
GLA P06280 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
CDK4 P11802 10/20 0.41
CCND1 P24385 10/20 0.41
CCND2 P30279 8/20 0.41
CCND3 P30281 8/20 0.41
WEE1 P30291 1/20 0.39
PAK4 O96013 1/20 0.38
PAK1 Q13153 1/20 0.38
PKN1 Q16512 1/20 0.38
CCNA2 P20248 3/20 0.38
CDK2 P24941 3/20 0.38
JAK3 P52333 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189859 0.87 CCND3 (0.54) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL189169 0.83 KDM4E (0.58) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL190014 0.83 KDM4E (0.58) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL188921 0.81 MAPK1 (0.58) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL189897 0.81 KDM4E (0.57) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL188366 0.78 MAPK1 (0.52) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL4355205 0.78 KDM4E (0.50) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL11928210 0.76 KDM4E (0.47) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL188696 0.76 CDK4 (0.47) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL189479 0.74 ALDH1A1 (0.66) ALDH1A1KDM4EGAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER Exelixis, Inc. (US) 2009-05-13 EP claimed
WO-2008021389-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS, INC. (US) 2008-02-21 WO claimed